يعرض 1 - 10 نتائج من 30 نتيجة بحث عن '"McCaskill, Reva"', وقت الاستعلام: 0.72s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المصدر: Mease , P , Setty , A , Papp , K , Van den Bosch , F , Tsuji , S , Keiserman , M , Carter , K , Li , Y , McCaskill , R , McDearmon-Blondell , E , Wung , P & Tillett , W 2023 , ' Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics : 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study ' , Clinical and Experimental Rheumatology , vol. 41 , pp. 2286-2297 . https://doi.org/10.55563/clinexprheumatol/8l7bbkTest

  2. 2
    مؤتمر

    جغرافية الموضوع: Virtual

    الوقت: 2021-05-21 to 2021-05-23

    العلاقة: Internal Medicine Journal; Australian Rheumatology Association 61st Annual Scientific Meeting; Nash, P; Richette, P; Gossec, L; Marchesoni, A; Kato, K; Blondell, E; Lesser, E; McCaskill, R; Feng, D; Anderson, J; Ruderman, E, UPADACITINIB AS Upadacitinib as monotherapy and in combination with non-biologic dmards for the treatment of psoriatic arthritis: subgroup analysis from two phase 3 trials, Internal Medicine Journal, 2021, 51, pp. 44-45; http://hdl.handle.net/10072/405169Test

  3. 3
    مؤتمر

    جغرافية الموضوع: Sydney, Australia

    الوقت: 2021-05-21 to 2021-05-23

    العلاقة: Internal Medicine Journal; Australian Rheumatology Association Annual Scientific Meeting with the Rheumatology Health Professionals Association; Burmester, G; Winthrop, K; Nash, P; Goupille, P; Azevedo, VF; Salvarani, C; McCaskill, RM; Liu, J; Pierre-Louis, BJ; Anderson, JK; Ruderman, E, Safety Profile of Upadacitinib in Psoriatic Arthritis: Integrated Analysis from Two Phase 3 Trials, Internal Medicine Journal, 2021, 51, pp. 46-46; http://hdl.handle.net/10072/405122Test

  4. 4
    مؤتمر

    جغرافية الموضوع: Online

    الوقت: 2020-11-05 to 2020-11-09

    العلاقة: Arthritis & Rheumatology; ACR Convergence 2020; Nash, P; Richette, P; Gossec, L; Marchesoni, A; Kato, K; Blondell, E; Lesser, E; McCaskill, RM; Feng, D; Anderson, JK; Ruderman, E, Upadacitinib as Monotherapy and in Combination with Non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Analysis from Two Phase 3 Trials, Arthritis & Rheumatology, 2020, 72 (S10), pp. 2709-2712; http://hdl.handle.net/10072/423010Test

  5. 5
    مؤتمر

    جغرافية الموضوع: Virtual

    الوقت: 2020-11-05 to 2020-11-09

    العلاقة: Arthritis & Rheumatology; ACR Convergence 2020; Burmester, G; Winthrop, K; Nash, P; Goupille, P; Azevedo, VF; Salvarani, C; McCaskill, RM; Liu, J; Pierre-Louis, BJ; Anderson, JK; Ruderman, E, Safety Profile of Upadacitinib in Psoriatic Arthritis: Integrated Analysis from Two Phase 3 Trials, Arthritis & Rheumatology, 2020, 72 (S10), pp. 2721-2723; http://hdl.handle.net/10072/403655Test

  6. 6
    دورية أكاديمية

    المساهمون: Griffith University Brisbane, Hôpital Lariboisière-Fernand-Widal APHP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Biologie de l'Os et du Cartilage : Régulations et Ciblages Thérapeutiques (BIOSCAR (UMR_S_1132 / U1132)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), University of Rochester Medical Center (URMC), Abbvie Inc. North Chicago, Feinberg School of Medicine, Northwestern University Evanston

    المصدر: ISSN: 1462-0324.

  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية

    المصدر: Mease , P J , Lertratanakul , A , Anderson , J K , Papp , K , Van den Bosch , F , Tsuji , S , Dokoupilova , E , Keiserman , M , Wang , X , Zhong , S , McCaskill , R M , Zueger , P , Pangan , A L & Tillett , W 2021 , ' Upadacitinib for psoriatic arthritis refractory to biologics : SELECT-PsA 2 ' , Annals of the Rheumatic Diseases , vol. 80 , pp. 312-320 . https://doi.org/10.1136/annrheumdis-2020-218870Test

  9. 9
    دورية أكاديمية
  10. 10
    دورية أكاديمية